The Federal Circuit recently vacated and remanded a district court’s grant of summary judgment invalidating Nevro Corp.'s patent claims, holding that “[t]he test for indefiniteness is "whether ...

It has been about a month since the last earnings report for Nevro (NVRO). Shares have added about 0.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Nevro (NVRO) shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Nevro Corp. shares have significantly underperformed, selling 57% lower than in 2021. The company's top-line momentum continues, but it faces economic challenges and lacks value creation for ...

Reports Q3 revenue $96.9M, consensus $93.07M. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects ...

Nevro is an intriguing stock.It has been struggling to escape the downdrafts endemic to pandemic era medicine. It has interesting, state of the art, FDA approved SCS medical device systems, but ...

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.